B cells

[Allogene Therapeutics, Inc.] Allogene Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic CAR T therapies for cancer, announced that the US FDA has granted ODD to ALLO-715 for the treatment of MM.

[eLife] Scientists established two murine Ebf1-deficient pro-B cell lines, with and without T-lineage potential. The latter expressed lower levels of Lmo2; their potential was restored via ectopic expression of Lmo2.

[Immunity] Researchers investigated how forkhead box O1 (FOXO1) mutations targeting a regulatory axis in germinal center-derived B cell non-Hodgkin lymphomas contributed to lymphomagenesis.

[Leukemia] Using a mouse model with a gain-of-function CXCR4 mutation that hyperactivated CXCR4 signaling, scientists identified CXCR4 as a crucial activator of multiple key oncogenic pathways.

[PLOS Pathogens] Investigators identified a major EBNA2 binding site downstream of the CIITA gene and upstream of DEXI, a dexamethasone inducible gene that is oriented head-to-head with CIITA gene transcripts.

[Blood Cancer Journal] The authors evaluated the safety and immunogenicity of BNT162b2 vaccine in patients with hematological malignancies.